Samsung C&T and Samsung Electronics have taken a step forward with GRAIL, Inc. by signing a strategic collaboration to bring the Galleri early cancer detection test to major Asian markets. This agreement involves an investment of 110 million dollars by Samsung, acquiring shares of GRAIL at $70.05 each.
Jaywoo Kim, senior executive at Samsung C&T, emphasized that the joint effort represents more than just an investment, marking a milestone in cancer detection and delivering innovative technology to customers in South Korea and beyond. The alliance seeks to commercialize the Galleri test in South Korea, with a view to Japan and Singapore, with the initial tests taking place in North Carolina, USA.
Sir Harpal Kumar, president of GRAIL, expressed his enthusiasm for the partnership, highlighting the opportunity to improve its finances and to advance the test's reimbursement in key markets. Samsung and GRAIL also explore integrating Samsung's data technology with GRAIL's innovations.
Hon Pak, from Samsung Electronics, stated that this collaboration is part of a vision to improve health globally, planning to integrate Samsung's artificial intelligence with GRAIL's data for a personalized experience. It is anticipated that the definitive terms of the agreement will be concluded by 2026, with GRAIL handling the exclusive distribution of the test in Asia.
The investment and collaboration depend on final agreements and regulatory conditions, with the investment expected to be concluded in early 2026.
